



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/714,195	11/14/2003	Joffre B. Baker	GHDX-005	5745
24353	7590	09/08/2009		
BOZICEVIC, FIELD & FRANCIS LLP 1900 UNIVERSITY AVENUE SUITE 200 EAST PALO ALTO, CA 94303				EXAMINER
				SHAW, AMANDA MARIE
			ART UNIT	PAPER NUMBER
			1634	
			MAIL DATE	DELIVERY MODE
			09/08/2009	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Interview Summary</b>	<b>Application No.</b> 10/714,195	<b>Applicant(s)</b> BAKER ET AL.
	<b>Examiner</b> Amanda Shaw	<b>Art Unit</b> 1634

All participants (applicant, applicant's representative, PTO personnel):

(1) Amanda Shaw and Doug Schultz (in person).

(3) Joffre Baker (by telephone).

(2) Carl Francis (in person).

(4) Kathleen Determann (by telephone).

Date of Interview: 01 September 2009.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: 31.

Identification of prior art discussed: Airenne et al (1996) Genomics 32:54.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: The issues that were discussed are listed on the interview agenda (see attachment that was submitted by applicants. The examiner indicated that she would fully consider any arguments or evidence present in the next response regarding the issue of whether the claims are enabled for the following ErbB1 inhibitors: erlotinib, cetuximab, or gefitinib.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Amanda Shaw/